BarbaraADegarMD

Pediatric Hematology & Oncology • Boston, MA

Assistant Professor of Pediatrics, Dana-Farber Cancer Institute

Join to view full profile

Dr. Degar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Degar's full profile

Already have an account?

Office
44 Binney St
Jimmy Fund Clinic
Boston, MA 02115
Phone+1 617-632-6801

Fax+1 617-632-4811

Education & Training

Yale-New Haven Medical CenterFellowship, Pediatric Hematology/Oncology, 1994 - 1997
Yale-New Haven Medical CenterResidency, Pediatrics, 1991 - 1994
New York University School of MedicineClass of 1991

Certifications & Licensure

MA State Medical License 2001 - 2026
CT State Medical License 1996 - 2002
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2008 Aug 04
Completed
Phase 3
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis Start of enrollment: 2013 Jul 01
Completed
Phase 2, Phase 3
A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody Start of enrollment: 2014 Aug 04
Completed
Phase 2, Phase 3
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Start of enrollment: 2016 Nov 02
Recruiting
Phase 2, Phase 3
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE_NOT_RECRUITING
PHASE2
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2017 Jun 15
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Start of enrollment: 2021 Jul 13
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Start of enrollment: 2021 Apr 19
RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Histiocytic Disorders in Pediatric and Adult Patients.
Nancy Berliner, Barbara Degar
Hematology/oncology Clinics of North America. 2025-03-29
Over 4 decades, French children teach about LCH.
Barbara A Degar, Barrett J Rollins
Blood. 2025-03-06
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.
Richard J Marrero, Huiyun Wu, Xueyuan Cao, Phani Krishna Parcha, Abdelrahman H Elsayed
Clinical Cancer Research. 2024-10-01

Grant Support

Homeobox Gene Expressed In Hematopoietic Stem CellsNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2001
Gene Expression In Hematopoietic Stem CellsNational Institute Of Diabetes And Digestive And Kidney Diseases1997–1998

BarbaraADegarMD

Dr. Degar is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Grant Support

Viewing the full profile is available to verified healthcare professionals only.